

AYUSH-64

May 8, 2021

In news: The Ayush ministry has launched a massive nationwide campaign to distribute its proven poly herbal ayurvedic drug AYUSH 64 and Sidha medicine Kabasura Kudineer for the benefit of Covid patients in home isolation.

More information-

- It is recommended in **National Clinical Management Protocol** based on ayurveda and yoga which is vetted by National Task Force on Covid Management of ICMR and Guidelines for Ayurveda Practitioners for Covid-19 patients in home isolation.
- Kabasura Kudineer is included in Guidelines for Siddha Practitioners for Covid 19 issued by the ministry of Ayush.
- The Ministry of Ayush and CSIR collaboration recently completed the multi-centre clinical trial to evaluate the safety and efficacy of AYUSH 64 in the management of mild to moderate Covid-19 patients.
- The main **collaborator in the campaign is Sewa Bharati.**

About AYUSH-64-

- It is an Ayurvedic formulation which was developed by the **Central Council for Research in Ayurvedic Sciences (CCRAS)**, the apex body for research in Ayurveda under the Ministry of Ayush, for management of Malaria.
- This drug was repurposed as the **ingredients showed notable antiviral, immune-modulator and antipyretic properties.**
- The formulation has also shown very promising results in Influenza like illness.
- It can be taken by patients at any stage of the COVID-19 disease.
- It has been identified as a potential adjunct to

standard care in the management of *asymptomatic, mild and moderate COVID-19 without risk factors and those not requiring emergency interventions or hospitalization.*

- It is found to significantly reduce the duration for clinical recovery in terms of disease symptoms and severity.